TRDA · Entrada Therapeutics, Inc. · Executive Compensation
$5.48
+0.10 (+1.86%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$239.85M
Shares
38.94M
Volume · Oct 5
463.82K
Avg daily vol (3M)
360.55K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Dipal Doshi | Chief Executive Officer | $3,837,737 |
| Natarajan Sethuraman Ph. D | President of Research and Development | $2,254,315 |
| Nathan J. Dowden | President and Chief Operating Officer | $2,223,497 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Dipal Doshi | Chief Executive Officer | $3,891,503 |
| Nathan J. Dowden | President and Chief Operating Officer | $2,460,688 |
| Natarajan Sethuraman Ph. D | President of Research and Development | $1,962,700 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dipal Doshi | Chief Executive Officer | $3,735,466 |
| Natarajan Sethuraman Ph. D | President of Research and Development | $1,485,455 |
| Nathan J. Dowden | President and Chief Operating Officer | $1,485,455 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dipal Doshi | Chief Executive Officer | $3,491,063 |
| Natarajan Sethuraman Ph. D | Chief Scientific Officer | $1,618,915 |
| Nathan J. Dowden | President and Chief Operating Officer | $1,540,389 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dipal Doshi | President and Chief Executive Officer | $5,530,399 |
| Natarajan Sethuraman Ph. D | Chief Scientific Officer | $4,306,614 |
| Nathan J. Dowden | Chief Operating Officer | $2,312,017 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Natarajan Sethuraman Ph. D | Chief Scientific Officer | $579,765 |
| Nathan J. Dowden | Chief Operating Officer | $561,497 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Bernhardt Zeiher, M.D. | Class II director | Appointed | 2026-06-10 |
| Peter S. Kim, Ph.D. | Class II director | Appointed | 2026-06-10 |
| Maha Radhakrishnan | Class III director | Appointed | 2025-06-03 |
| Nathan J. Dowden | President | Appointed | 2024-01-03 |
| Kush M. Parmar, M.D., Ph.D. | member and the Chair of the Compensation Committee | Appointed | 2023-12-06 |
| Gina Chapman | member of the Audit Committee | Appointed | 2023-12-06 |
| John F. Crowley | member of the Board of Directors | Resigned | 2023-12-06 |
| Gina Chapman | member of the Nominating and Corporate Governance Committee | Appointed | 2023-08-10 |
| Gina Chapman | Class III director | Appointed | 2023-08-10 |
| Bernhardt Zeiher | Class II director | Appointed | 2023-06-08 |
| Peter S. Kim | Class II director | Appointed | 2023-06-08 |
| Todd Foley | member of the Company's Board of Directors | Resigned | 2023-06-08 |
| Bernhardt Zeiher | Class II director | Appointed | 2023-04-04 |